Transgene SA (OTCMKTS:TRGNF – Get Free Report) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 5 shares, a drop of 99.7% from the July 15th total of 1,507 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Transgene Stock Performance
TRGNF remained flat at $0.85 during midday trading on Tuesday. Transgene has a one year low of $0.85 and a one year high of $1.08. The company has a fifty day moving average of $0.85 and a two-hundred day moving average of $0.92.
About Transgene
Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.
The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity.
Featured Stories
- Five stocks we like better than Transgene
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
